ParcelBio

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to

shared extracted concept terms: disease; shared product terms: clinical, novel, therapie, disease; shared product theme: health and clinical care; shared affiliation: Y Combinator

Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified sm

shared extracted concept terms: disease; shared product terms: therapeutic, novel, protein, disease; shared product theme: health and clinical care; shared affiliation: Y Combinator

What we do? We develop digital therapeutics to address unmet medical needs in hematology and oncology. How it works? First we build networks of doctors and patients designed to track, predict and prevent disease. Second, we validate the safety and efficacy of our interventions in pivotal clinical studies to obtain regulatory clearance (SaMD). Finally, we aim to commercialize our products as prescription digital therapeutics (DTx). Where are we now? Today, we are the standard in digital hematolog

shared extracted concept terms: oncology; shared product terms: therapeutic, oncology, design, disease; shared product theme: health and clinical care; shared affiliation: Y Combinator

Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in

shared extracted concept terms: protein, therapeutic; shared product terms: protein, engineer, therapeutic; shared product theme: health and clinical care; shared affiliation: Y Combinator

Cancer is a genetic disease. We know this from decades of human and veterinary cancer research. Precision medicine and targeted therapies are successfully used to treat humans with cancer. At FidoCure®, we bring this approach to the world of veterinary medicine. FidoCure® empowers veterinarians to offer genetic sequencing and targeted therapies to treat dogs with cancer. We are committed to expanding the veterinary oncology toolbox for both diagnostics and therapeutics. Our veterinary partners h

shared product terms: disease, medicine, therapie, oncology; shared product theme: health and clinical care; same category: Developer tools; shared affiliation: Y Combinator

Augmenting mRNA therapeutics with a novel molecular toolkit.

shared product terms: mrna, therapeutic, novel; shared product theme: health and clinical care